drugset / Trial / NCT00633724

Multiple-Vaccine Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00633724

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical response of different doses of HLA-A\*2402 restricted epitope peptides URLC10, TTK, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

Timeline

Start
2007-05
Primary completion
2012-06
Completion
2012-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject CDCA1 Unknown 0.5 mg Subcutaneous
Subject CDCA1 Unknown 1 mg Subcutaneous
Subject CDCA1 Unknown 3 mg Subcutaneous
Subject URLC10 Peptide 0.5 mg Subcutaneous
Subject URLC10 Peptide 1 mg Subcutaneous
Subject URLC10 Peptide 3 mg Subcutaneous
Subject VEGFR1 Peptide 0.5 mg Subcutaneous
Subject VEGFR1 Peptide 1 mg Subcutaneous
Subject VEGFR1 Peptide 3 mg Subcutaneous
Subject VEGFR2 Peptide 0.5 mg Subcutaneous
Subject VEGFR2 Peptide 1 mg Subcutaneous
Subject VEGFR2 Peptide 3 mg Subcutaneous